share_log

君圣泰医药-B(02511.HK)完成HTD1801治疗2型糖尿病的III期临床试验患者入组

Patient enrollment has been completed for the Phase III clinical trial of HTD1801 for the treatment of type II diabetes by KunShengTai Pharmaceutical-B (02511.HK).

Gelonghui Finance ·  Jun 27 20:19

On June 27th, Gelon Hui reported that Junshengtai Medicine-B (02511.HK) announced that the company's independently developed intestinal and hepatic anti-inflammatory and metabolic regulator HTD1801 (berberine) has completed patient enrollment in two phase III clinical registration trials for type 2 diabetes (T2DM) patients.

The two phase III registration trials are as follows: HTD1801.PCT105: A multicenter, randomized, double-blind, placebo-controlled study (SYMPHONY-1) assessing the efficacy and safety of HTD1801 in type 2 diabetes patients with poor blood sugar control after diet and exercise intervention.

HTD1801.PCT106: A multicenter, randomized, double-blind, placebo-controlled study (SYMPHONY-2) evaluating the efficacy and safety of HTD1801 in type 2 diabetes patients with poor glycemic control on metformin.

In these two trials, the effects of HTD1801 on glycated hemoglobin and glucose metabolism, blood lipids, liver damage/inflammation markers, and inflammation indicators of T2DM patients will be evaluated.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment